Multiple Choice
Nationwide Pharmaceutical Corporation
A project with an up-front cost at t = 0 of $1500 is being considered by Nationwide Pharmaceutical Corporation (NPC) .(All dollars in this problem are in thousands.) The project's subsequent cash flows are critically dependent on whether a competitor's product is approved by the Food and Drug Administration.If the FDA rejects the competitive product, NPC's product will have high sales and cash flows, but if the competitive product is approved, that will negatively impact NPC.There is a 75% chance that the competitive product will be rejected, in which case NPC's expected cash flows will be $500 at the end of each of the next seven years (t = 1 to 7) .There is a 25% chance that the competitor's product will be approved, in which case the expected cash flows will be only $25 at the end of each of the next seven years (t = 1 to 7) .NPC will know for sure one year from today whether the competitor's product has been approved.
NPC is considering whether to make the investment today or to wait a year to find out about the FDA's decision.If it waits a year, the project's up-front cost at t = 1 will remain at $1,500, the subsequent cash flows will remain at $500 per year if the competitor's product is rejected and $25 per year if the alternative product is approved.However, if NPC decides to wait, the subsequent cash flows will be received only for six years (t = 2 ...7) .
-Refer to the data for Nationwide Pharmaceutical Corporation (NPC) .Calculate the effect of waiting on the project's risk, using the same data.By how much will delaying reduce the project's coefficient of variation? (Hint: Use the expected NPV.)
A) 2.23
B) 2.46
C) 2.70
D) 2.97
E) 3.27
Correct Answer:

Verified
Correct Answer:
Verified
Q4: Which of the following will NOT increase
Q5: Garner-Wagner Incorporated<br>The executives of Garner-Wagner Inc.are considering
Q6: Real options are most valuable when the
Q7: Real options exist when managers have the
Q8: Garner-Wagner Incorporated<br>The executives of Garner-Wagner Inc.are considering
Q10: Which of the following is NOT a
Q11: Which one of the following is an
Q12: Steppingstone Incorporated<br>The Z−90 project being considered by
Q13: The option to abandon a project is
Q14: Real options affect the size, but not